Literatur
Bedi M, Firat S, Semenenko VA et al (2012) Elective lymph node irradiation with intensity-modulated radiotherapy: is conventional dose fractionation necessary? Int J Radiat Oncol Biol Phys 83:e87–e92
Nuyts S, Lambrecht M, Duprez F et al (2013) Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiother Oncol 109:323–329
Garattini S, Bertelè V (2007) Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 370:1875–1877
Salama JK, Stenson KM, Kistner EO et al (2008) Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 19:1787–1794
Langendijk JA, Doornaert P, Rietveld DH et al (2009) A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 90:189–195
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Hreib und M. Krause geben an, dass kein Interessenkonflikt besteht.
Additional information
Originalpublikation
Nuyts S, Lambrecht M, Duprez F, et al (2013) Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiother Oncol 109:323–329
Rights and permissions
About this article
Cite this article
Hreib, M., Krause, M. Kein Nachweis einer reduzierten Spättoxizität durch Dosisreduktion im elektiven Lymphknotenbereich in der primären Radiochemotherapie von Kopf-Hals-Tumoren. Strahlenther Onkol 194, 697–698 (2018). https://doi.org/10.1007/s00066-018-1312-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-018-1312-4